VERVE THERAPEUTICS

In 2018, Verve was founded by cardiology, gene editing and drug development pioneers seeking to find a solution for the global epidemic that is cardiovascular disease (CVD). Despite improvements to treatment and care over the last several decades, CVD remains the leading cause of death worldwide... At Verve, we are striving to build the preeminent company developing gene editing medicines to treat atherosclerotic cardiovascular disease (ASCVD). We are leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of this condition that touches so many individuals worldwide, whether personally or through a loved one. Our goal is to disrupt the chronic care model for treating ASCVD by providing a new therapeutic approach with single-course gene editing medicines... Verve is meeting this challenge head-on through the development of groundbreaking, single-course gene editing medicines.

Also known as: Verve, Verve Therapeutics, Inc.

Primary location: Boston United States